Send us a text Join us as we unwind in the Christmas Holiday period with a masterful overview of PARP inhibitors in metastatic prostate cancer with Professor Rob Jones. Rob is an old friend of the show and is amazing at setting the scene for who & when PARP inhibitors can be useful in metastatic prostate cancer.

Send us a text Welcome back! In part 1 we discussed the major effects of menopause and how these can be worsened by hormonal medications given to treat breast cancer and the impact these can have on patients completing treatment as planned. In this episode we welcome back Dr Rebecca Bowen and discuss practical advice on managing these symptoms including a link to what will be a vital resource for all clinicians in Oncology and Primary Care: the Meno.Pause app. Link below, download today! Me...

Send us a text When is it safe to giving HRT in women who are being treated or have previously been diagnosed with breast cancer? Will the use of vaginal oestrogens affect breast cancer outcomes? What is the trade off on quality of life when symptoms of the menopause aren't managed? Did you know that roughly 1 in 4 women stop their hormone therapy for breast cancer due to menopausal side effects!! Who better to answer these questions and more than Dr Rebecca Bowen, Consultant Oncologist in Ro...

Send us a text Sexual health in cancer is a topic we need to talk more about. So many patients feel unable to discuss their sexual health and also clinical teams don’t also mange to bring the topic up. A cancer diagnosis can affect self image and confidence. We talk to Lorraine Grover who is a sexual health specialist nurse about how we can break down some of these barriers. Erectile dysfunction and much more discussed. You may never look at a Calypo ice lolly the same again !! This epi...

Send us a text We return to Part 2 of our walk through metastatic bowel cancer with the excellent Professor Naureen Starling. We look at RAS, BRAF and future directions for treatment of metastatic bowel cancer. Can ctDNA have a role in metastatic bowel cancer? What role may HER2 have to play going forward? What is exciting on the horizon in mCRC? Enjoy!!

Send us a text

Send us a text Join us as we return for Part 2 with the superb Dr Alison Berner. It’s Transgender Awareness Week and we discuss resources to support patients and clinicians. We discuss OUTpatients and UCATS - UK cancer and transition service.

Send us a text As we approach transgender awareness week we discuss cancer care in the transgender community with the exceptional Dr Alison Berner. 1 in 40 people aged under 30 identify as transgender in recent census. How we give support needed and signpost patients can have a huge influence on their experience of care. Alison has done so much work in this area. We learned a lot in this episode and we hope you enjoy! https://outpatients.org.uk/ https://www.wearetransplus.co.uk/uk-cancer-an...

Send us a text We return to discuss stereotactic radiotherapy (SABR) in prostate cancer with the superb Dr Alison Tree from The Royal Marsden Hospital. We discuss the findings of the TRAP study which extended time to next treatment by 6 months when SABR was used for sites of growing disease. Do we always need to change systemic therapy when only one or two sites of metastatic disease is growing??

Send us a text We are back for part 2 to finish our journey through the Gut Microbiome with the excellent Professor Monty Pal !! Few areas of cancer treatment have generated as much interest as the Gut Microbiome in recent years. We discuss work done by Monty's team on CBM588 on immunotherapy in kidney cancer. CBM 588 is a live bacterial product that is available in health shops in Japan where it is used to promote a healthy gut. Monty's team found incredible results where it improved r...

Send us a text Did you know that we have more bacterial DNA than human DNA in our bodies. This is because our guts contain trillions of bacteria and are now being thought of as another organ of the body. Join us this week as we discuss the Gut Microbiome (part 1 of 2) and its importance on drugs like immunotherapy response in cancer. We talk to none other than the excellent Professor Monty Pal from The City of Hope Hospital in California. Monty is an internationally respected kidney cancer ex...

Send us a text Did you know that the lifetime risk of prostate cancer in a black man is 1 in 4 ? That’s twice the risk of prostate cancer in a white man. Did you know that men in Scotland are twice as likely to have advanced prostate cancer compared to those in the South of England? Professor Frank Chinewungdoh is a man on a mission. He is trying to make prostate cancer testing as possible to men across all groups. He makes an argument for prostate cancer screening and measures to make ...

Send us a text We are back to finish our journey through cancer vaccines with Dr Lennard Lee. We celebrate some of the heroes of UK cancer vaccine trials from centres Big & Small. Lennard gives us all some hope for the future. We now are officially Watching This Space for more Cancer Vaccine Trial results.

Send us a text Cancer Vaccines are Here!! We talk to a man who is on a mission! Dr Lennard Lee - associate Professor at Oxford University Hospital. Lennard has a vision where we use the technologies developed in Vaccines during COVID and turn them into effective treatments for cancer. This is some space age stuff but its HERE, its EXCITING, its HAPPENING!!

Send us a text We return on our odyssey through Rectal Cancer with the amazing Professor Richard Adams from Velindre cancer Centre, Cardiff. In this episode we discuss the immunotherapy revolution in the subgroup of rectal cancer that is MSI-High. We discuss future directions in rectal cancer. We also give Richard a wish - AND HE GOES BIG!!! What a treat to have these 2 episodes with Richard!

Send us a text In this episode we venture in to a new tumour site: Colorectal Cancer. We are joined by internationally renowned oncologist Professor Richard Adams from Velindre Cancer Centre. In Part 1 we dive in to treatment of localised rectal cancer, with a comprehensive overview of the role of radiotherapy, contact brachytherapy and total neodjuvant therapy. We also explore the evolving evidence of non-operative management of rectal cancer. We look into the OPERA (EU), OPRA ...

Send us a text Biliary Tract Cancers - Cholangiocarcinomas and Gallbladder cancers are often seen as rare and aggressive cancers. 🎙️We tackle Biliary Tract Cancers with the exceptional Professor John Bridgewater. 🎙️Few people are as knowledgable & linked to a cancer as Prof Bridgewater is to cholangiocarcinoma. 🎙️Prof Bridgewater has led practice changing studies in this area and is an internationally renowned expert. 🎙️This group of cancers is more common than you think! 🎙️If you don’...

Send us a text

Send us a text We discuss Early Phase Clinical Trials with Dr Natalie Cook from the Christie Early Trials Unit. We learn how molecular profiling is shaping early phase trials and how future trials may be shaped.

Send us a text Clinical Trials are the Stepping Stones for the progress we have made over the years in the treatment of cancer. We talk to Dr Mohini Varughese who is heavily involved in clinical trials in urology and passionate about the delivery of clinical trials across oncology. We discuss: 🎙️Phase 1,2 &3 trials 💊The benefits for patients 💉The benefits for clinical teams